SEC Form 4 · accession 0001209191-18-062513

GENOMIC HEALTH INC · GHDX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

G Bradley Cole

Officer — CFO

Period of report

Dec 11, 2018

Accepted (ET)

Dec 13, 2018 · 6:24 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001131324

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Dec 6, 2018	G	1,633	$0.00	D	44,047	I	Held by the Cole Family Trust
Common Stock^F1	Dec 11, 2018	M	10,000	$22.98	A	54,047	I	Held by the Cole Family Trust
Common Stock^F1	Dec 11, 2018	M	5,000	$17.18	A	59,047	I	Held by the Cole Family Trust
Common Stock^F2,F3,F4,F1	Dec 11, 2018	S	2,529	$70.5843	D	56,518	I	Held by the Cole Family Trust
Common Stock^F2,F3,F5,F1	Dec 11, 2018	S	4,571	$71.5372	D	51,947	I	Held by the Cole Family Trust
Common Stock^F2,F3,F6,F1	Dec 11, 2018	S	700	$72.7289	D	51,247	I	Held by the Cole Family Trust
Common Stock^F2,F3,F7,F1	Dec 11, 2018	S	900	$73.5567	D	50,347	I	Held by the Cole Family Trust
Common Stock^F2,F3,F8,F1	Dec 11, 2018	S	1,300	$74.6092	D	49,047	I	Held by the Cole Family Trust
Common Stock^F9,F3,F10,F1	Dec 11, 2018	S	1,400	$70.6059	D	47,647	I	Held by the Cole Family Trust
Common Stock^F9,F3,F11,F1	Dec 11, 2018	S	2,200	$71.5309	D	45,447	I	Held by the Cole Family Trust
Common Stock^F9,F3,F12,F1	Dec 11, 2018	S	600	$73.0951	D	44,847	I	Held by the Cole Family Trust
Common Stock^F9,F3,F13,F1	Dec 11, 2018	S	800	$74.4225	D	44,047	I	Held by the Cole Family Trust

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F14	$17.18	Dec 11, 2018	M	5,000	D	—	Feb 18, 2020	Common Stock	5,000	36,471	D
Employee Stock Option (right to buy)^F15	$22.98	Dec 11, 2018	M	10,000	D	—	Jan 27, 2021	Common Stock	10,000	46,424	D

Explanation of responses

F1Includes an aggregate of 16,534 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
F10Represents weighted average sale price. Actual sale prices ranged from $70.07 to $71.05.
F11Represents weighted average sale price. Actual sale prices ranged from $71.11 to $72.05.
F12Represents weighted average sale price. Actual sale prices ranged from $72.65 to $73.45.
F13Represents weighted average sale price. Actual sale prices ranged from $73.96 to $74.91.
F14The option became exercisable as to 25% of the shares on February 18, 2011, and became exercisable as to 1/48th of the shares each full month thereafter.
F15The option became exercisable as to 25% of the shares on January 27, 2012, and became exercisable as to 1/48th of the shares each full month thereafter.
F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 23, 2018.
F3Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
F4Represents weighted average sale price. Actual sale prices ranged from $70.08 to $71.07.
F5Represents weighted average sale price. Actual sale prices ranged from $71.11 to $72.05.
F6Represents weighted average sale price. Actual sale prices ranged from $72.11 to $72.97.
F7Represents weighted average sale price. Actual sale prices ranged from $73.14 to $74.00.
F8Represents weighted average sale price. Actual sale prices ranged from $74.29 to $75.22.
F9These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on June 4, 2018.